Oxytocin Treatment of Schizophrenia (OTS)
Status
Conditions
Treatments
Details and patient eligibility
About
Purpose: Test whether intranasal administration of the neuropeptide, oxytocin, improves social cognition, social functioning and decreases paranoia and other psychotic symptoms in schizophrenia.
Participants: Up to 80 adults with schizophrenia for at least one year and with a high rating for paranoia.
Procedures (methods): Oxytocin or placebo will be administered twice daily in an intranasal spray (6 insufflations/dose or 24 IU) for 6 weeks. Before, during and at the end of the trial, each subject will undergo social cognitive measures (primary outcomes) and psychiatric symptom ratings (secondary outcomes).
Full description
Inclusion criteria: meeting Diagnostic and Statistical Manual IV (DSM-IV) criteria for paranoid or undifferentiated schizophrenia for at least 1 year; scoring > 4 on the suspiciousness/persecution (hereafter referred to as paranoia) subscale of the Positive and Negative Symptom Scale (PANSS) or 3 on the paranoia subscale and > 3 on the hostility, active social avoidance, passive/apathetic social withdrawal or uncooperativeness subscale and > 60 on the full PANSS: stability of symptom severity and on the same medication(s) and dose(s) for at least 1 month; low to moderate depressive symptoms.
Exclusion criteria: low literacy as indicated by an inability to read and understand the consent form; dependence on substances other than tobacco or caffeine; positive urine drug screen for illegal substances or drugs that have not been prescribed; debilitating medical conditions (including AIDS; HIV infection alone will not be grounds for exclusion); major surgery or trauma in the past year will be grounds for exclusion although subjects determined to be recovered and stable may be included at the discretion of the Principal Investigator (PI); pregnancy, breast-feeding; having given birth in the past 6 months or breast-feeding in the past 3 months. Individuals judged unable to learn self-administration of intranasal treatments and/or not sufficiently reliable to do so will be excluded. Abnormalities found during medical evaluation will be grounds for exclusion (see details below) although subjects with laboratory measures somewhat out of the normal range may be included at the discretion of Drs. Pedersen, Gilmore, Rau and/or Salimi.
Study Design: Randomized, double-blind, placebo-controlled design. Up to 80 subjects will complete the protocol: 40 will receive oxytocin; 40 placebo. Prior to the treatment trial, baseline measures will be obtained. Social cognition and psychiatric symptoms will be measured at Baseline and at 6 weeks of the 6 week treatment trial.
Procedures: Subjects will be recruited from the University of North Carolina (UNC) Department of Psychiatry outpatient clinics and the community. If total Positive and Negative Symptoms Scale (PANSS) score is > or equal to 60, PANSS sub-score for suspiciousness/persecution is > or equal to 4, their medical history will be reviewed including medications and dosages over the past month. If they do not have exclusionary medical or medication history, their psychiatric history will be reviewed. If necessary to confirm their diagnosis, they will undergo the Structured Clinical Interview for DSM-IV (SCID) patient version. If they have met criteria for schizophrenia, paranoid or undifferentiated type, for at least one year, they will undergo a physical exam and blood will be drawn and urine collected for laboratory measures including complete blooc count (CBC), electrolytes, blood urea nitrogen (BUN), creatinine, liver function tests, glucose, thyroid-stimulating hormone (TSH), urinanalysis, urine drug screen and pregnancy test. This initial evaluation may require up to 3-4 hours. Prospective subjects will be encouraged to rest for 20-30 minutes between the initial interviews (PANSS, SCID) and the history, physical exam and blood/urine collections. Psychiatric, medical and medication history will be confirmed by reviewing medical records and contacting clinicians in charge of the prospective subject's psychiatric care. The initial evaluation will be conducted in the Clinical and Translational Research Center (CTRC) outpatient clinic or at the UNC Psychiatry Clinical Research Unit (CRU) at Central Regional Hospital (Raleigh or Butner).
SCID, PANSS, other psychological results and medical labs and history will be reviewed during conferences with Dr. Pedersen accompanied by Drs. Gilmore, Salimi and/or Rau. Consensus decisions will be made during these conferences about whether subjects meet the diagnostic and other criteria for inclusion in the study.
For subjects who meet study criteria, baseline measurements of social cognition, social competence, social functioning, paranoia, other psychotic and psychiatric symptoms will be obtained.
During the treatment trial, twice daily test treatments will be self-administered by subjects in the morning shortly after breakfast and late in the afternoon/early evening prior to dinner. Each treatment will consist of 6 insufflations (3/nostril alternating between nostrils) of Syntocinon Spray (Novartis), which contains approximately 24 international units (IU) of oxytocin, or placebo. There will be a 30-60 second pause between each insufflation. The placebo solution will be a solution that has all ingredients in Syntocinon Spray except for oxytocin in 2 oz vials containing 30 ml of solution designed to deliver 0.1 ml metered volume per insufflation. Treatment assignments will be random within each gender.
Social cognition and competence testing will begin 50 min after the morning treatment at 6 weeks (day 42) of the treatment trial and will be followed by ratings of psychotic, mood and anxiety symptoms (requiring 1-3 hr depending on how much social cognition testing is done). The Emotion Recognition-40, Reading the Mind in the Eyes test (Eyes Test), Interpersonal Reactivity Index and Trustworthiness Tasks, Brune Theory of Mind Task, as well as psychiatric ratings will be conducted at all time points.
Participants will be trained by research nurses during their first dosing with test substance in intranasal self-administration shortly after baseline measurements are completed. They will also be given written instructions about the timing of each day's test treatments and other procedures to follow at home. They will be given one 2 ounce vial containing 30 ml of test substance to last until their first outpatient clinic testing appointment and instructed when to begin the twice daily intranasal treatments. They will self administer test substance at the site so staff can confirm they are using proper technique. In addition to social cognition/competence testing and psychiatric ratings, blood samples as well as vital signs will be obtained during these visits. At 40 min after the last intranasal insufflation, blood (15 ml) will be drawn to measure plasma oxytocin concentrations and other lab values (sodium, potassium, glucose [treatment day 42], CBC, BUN, creatinine, liver function tests [treatment days 42]). An electrocardiogram (ECG) will also be obtained on the morning of treatment days 42 approximately 3-4 hr after intranasal treatment (when social cognition/competence testing and psychiatric ratings are completed). Urine will also be collected from female subjects on the day of baseline measurements and on treatment day 42 for pregnancy testing. These same procedures will conducted on the morning of treatment day 42 in participants studied as inpatients.
After procedures at the study site on the morning of treatment days 14 and 28, outpatient subjects will be given a new vial containing 30 ml test substance so they can self administer doses twice daily until their next visit to the study site. Subjects will be instructed to store vials at room temperature and to clean the tip of the spray nozzle with an alcohol wipe after each dose is administered. Vials will be weighted before dispensing and upon return to the clinic 2 wks later to determine how much solution was actually ejected from the vial.
Measurements: A battery of well-validated instruments to quantify psychiatric symptoms, social cognition and social competence will be used in this study.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Meeting DSM-IV criteria for paranoid or undifferentiated schizophrenia for at least 1 year.
- Scoring > or equal to 4 on the suspiciousness/persecution (paranoia) subscale of the Positive and Negative Symptoms Scale (PANSS), a full PANSS score > or equal to 60: stability of symptom severity and on the same medication(s) and dose(s) for at least 1 month; low to moderate depressive symptoms.
Exclusion criteria
- Low literacy as indicated by an inability to read and understand the consent form.
- Dependence on substances other than tobacco or caffeine.
- Positive urine drug screen for illegal substances or drugs that have not been prescribed.
- Debilitating medical conditions (including AIDS; HIV infection alone will not be grounds for exclusion).
- Major surgery or trauma in the past year will be grounds for exclusion although subjects determined to be recovered and stable may be included at the discretion of the PI.
- Pregnancy, breast-feeding.
- Having given birth in the past 6 months or breast-feeding in the past 3 months.
- Individuals judged unable to learn self-administration of intranasal treatments and/or not sufficiently reliable to do so will be excluded.
- Abnormalities found during medical evaluation will be grounds for exclusion although subjects with laboratory measures barely outside the normal range may be included at the discretion of the Principal Investigator.
Trial design
Primary purpose
Allocation
Interventional model
Masking
17 participants in 2 patient groups, including a placebo group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal